A Randomized Study of Methanol-Extraction Residue of Bacille Calmette-Guerin as Postsurgical Adjuvant Therapy of Uveal Melanoma
A randomized controlled clinical trial of methanol-extracted residue of bacille Calmette-Guerin adjuvant treatment of posterior uveal melanoma was undertaken. Of 113 patients, 34 patients received adjuvant immunotherapy and 79 patients received no treatment. No difference in survival was observed be...
Gespeichert in:
| Veröffentlicht in: | American journal of ophthalmology 1990-11, Vol.110 (5), p.522-526 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 526 |
|---|---|
| container_issue | 5 |
| container_start_page | 522 |
| container_title | American journal of ophthalmology |
| container_volume | 110 |
| creator | McLean, Ian W. Berd, David Mastrangelo, Michael J. Shields, Jerry A. Davidorf, Frederick H. Grever, Michael Makley, Torrance A. Gamel, John W. |
| description | A randomized controlled clinical trial of methanol-extracted residue of bacille Calmette-Guerin adjuvant treatment of posterior uveal melanoma was undertaken. Of 113 patients, 34 patients received adjuvant immunotherapy and 79 patients received no treatment. No difference in survival was observed between the adjuvant-treated group and the control group of patients. This study found that the size of the tumor was a highly significant risk factor for death caused by metastasis of uveal melanomas. The standard deviation of the nucleolar area of the neoplastic cells was a significant risk factor, even though patients with tumors composed of Callender's spindle-type cells were not included in the study. |
| doi_str_mv | 10.1016/S0002-9394(14)77876-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80116227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002939414778766</els_id><sourcerecordid>80116227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c360t-2e99db4f3853e86e83f5eb0d6cb80c4ee10931c30241407d1885ec3d8d3aecc33</originalsourceid><addsrcrecordid>eNqFkElPwzAQhS0EgrL8BCSfEBwCduw6zgmVqiwSCMRytlx7AkZJXGynAi78ddJFXDmNRu_Nm5kPoUNKTimh4uyJEJJnJSv5MeUnRSELkYkNNKCyKDMqS7qJBn-WHbQb43vfioIX22g7zzmhrBygnxF-1K31jfsGi59SZ7-wr_AdpDfd-jqbfKagTXK-xY8Qne1gIV9o4-oa8FjXDaQE2VUHwbVYR_zgY4pdeHVG13hk37u5bhN-foOgZ8volzn0yh3UfX6j99FWpesIB-u6h14uJ8_j6-z2_upmPLrNDBMkZTmUpZ3yiskhAylAsmoIU2KFmUpiOAAlJaOGkZxTTgpLpRyCYVZapsEYxvbQ0Sp3FvxHBzGpxkUDdX8F-C4qSSgVeV70xuHKaIKPMUClZsE1OnwpStQCvFqCVwuqinK1BK9EP3e4XtBNG7B_U2vSvX6-0qH_cu4gqGgctAasC2CSst79s-EXPI6UHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80116227</pqid></control><display><type>article</type><title>A Randomized Study of Methanol-Extraction Residue of Bacille Calmette-Guerin as Postsurgical Adjuvant Therapy of Uveal Melanoma</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>McLean, Ian W. ; Berd, David ; Mastrangelo, Michael J. ; Shields, Jerry A. ; Davidorf, Frederick H. ; Grever, Michael ; Makley, Torrance A. ; Gamel, John W.</creator><creatorcontrib>McLean, Ian W. ; Berd, David ; Mastrangelo, Michael J. ; Shields, Jerry A. ; Davidorf, Frederick H. ; Grever, Michael ; Makley, Torrance A. ; Gamel, John W.</creatorcontrib><description>A randomized controlled clinical trial of methanol-extracted residue of bacille Calmette-Guerin adjuvant treatment of posterior uveal melanoma was undertaken. Of 113 patients, 34 patients received adjuvant immunotherapy and 79 patients received no treatment. No difference in survival was observed between the adjuvant-treated group and the control group of patients. This study found that the size of the tumor was a highly significant risk factor for death caused by metastasis of uveal melanomas. The standard deviation of the nucleolar area of the neoplastic cells was a significant risk factor, even though patients with tumors composed of Callender's spindle-type cells were not included in the study.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/S0002-9394(14)77876-6</identifier><identifier>PMID: 2240139</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adjuvants, Immunologic - therapeutic use ; Aged ; BCG Vaccine - therapeutic use ; Female ; Humans ; Male ; Melanoma - mortality ; Melanoma - secondary ; Melanoma - surgery ; Melanoma - therapy ; Middle Aged ; Postoperative Care ; Prognosis ; Proportional Hazards Models ; Risk Factors ; Survival Analysis ; Uveal Neoplasms - mortality ; Uveal Neoplasms - surgery ; Uveal Neoplasms - therapy</subject><ispartof>American journal of ophthalmology, 1990-11, Vol.110 (5), p.522-526</ispartof><rights>1990 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c360t-2e99db4f3853e86e83f5eb0d6cb80c4ee10931c30241407d1885ec3d8d3aecc33</citedby><cites>FETCH-LOGICAL-c360t-2e99db4f3853e86e83f5eb0d6cb80c4ee10931c30241407d1885ec3d8d3aecc33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9394(14)77876-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2240139$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McLean, Ian W.</creatorcontrib><creatorcontrib>Berd, David</creatorcontrib><creatorcontrib>Mastrangelo, Michael J.</creatorcontrib><creatorcontrib>Shields, Jerry A.</creatorcontrib><creatorcontrib>Davidorf, Frederick H.</creatorcontrib><creatorcontrib>Grever, Michael</creatorcontrib><creatorcontrib>Makley, Torrance A.</creatorcontrib><creatorcontrib>Gamel, John W.</creatorcontrib><title>A Randomized Study of Methanol-Extraction Residue of Bacille Calmette-Guerin as Postsurgical Adjuvant Therapy of Uveal Melanoma</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>A randomized controlled clinical trial of methanol-extracted residue of bacille Calmette-Guerin adjuvant treatment of posterior uveal melanoma was undertaken. Of 113 patients, 34 patients received adjuvant immunotherapy and 79 patients received no treatment. No difference in survival was observed between the adjuvant-treated group and the control group of patients. This study found that the size of the tumor was a highly significant risk factor for death caused by metastasis of uveal melanomas. The standard deviation of the nucleolar area of the neoplastic cells was a significant risk factor, even though patients with tumors composed of Callender's spindle-type cells were not included in the study.</description><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Aged</subject><subject>BCG Vaccine - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Melanoma - mortality</subject><subject>Melanoma - secondary</subject><subject>Melanoma - surgery</subject><subject>Melanoma - therapy</subject><subject>Middle Aged</subject><subject>Postoperative Care</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>Uveal Neoplasms - mortality</subject><subject>Uveal Neoplasms - surgery</subject><subject>Uveal Neoplasms - therapy</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkElPwzAQhS0EgrL8BCSfEBwCduw6zgmVqiwSCMRytlx7AkZJXGynAi78ddJFXDmNRu_Nm5kPoUNKTimh4uyJEJJnJSv5MeUnRSELkYkNNKCyKDMqS7qJBn-WHbQb43vfioIX22g7zzmhrBygnxF-1K31jfsGi59SZ7-wr_AdpDfd-jqbfKagTXK-xY8Qne1gIV9o4-oa8FjXDaQE2VUHwbVYR_zgY4pdeHVG13hk37u5bhN-foOgZ8volzn0yh3UfX6j99FWpesIB-u6h14uJ8_j6-z2_upmPLrNDBMkZTmUpZ3yiskhAylAsmoIU2KFmUpiOAAlJaOGkZxTTgpLpRyCYVZapsEYxvbQ0Sp3FvxHBzGpxkUDdX8F-C4qSSgVeV70xuHKaIKPMUClZsE1OnwpStQCvFqCVwuqinK1BK9EP3e4XtBNG7B_U2vSvX6-0qH_cu4gqGgctAasC2CSst79s-EXPI6UHg</recordid><startdate>19901115</startdate><enddate>19901115</enddate><creator>McLean, Ian W.</creator><creator>Berd, David</creator><creator>Mastrangelo, Michael J.</creator><creator>Shields, Jerry A.</creator><creator>Davidorf, Frederick H.</creator><creator>Grever, Michael</creator><creator>Makley, Torrance A.</creator><creator>Gamel, John W.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19901115</creationdate><title>A Randomized Study of Methanol-Extraction Residue of Bacille Calmette-Guerin as Postsurgical Adjuvant Therapy of Uveal Melanoma</title><author>McLean, Ian W. ; Berd, David ; Mastrangelo, Michael J. ; Shields, Jerry A. ; Davidorf, Frederick H. ; Grever, Michael ; Makley, Torrance A. ; Gamel, John W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c360t-2e99db4f3853e86e83f5eb0d6cb80c4ee10931c30241407d1885ec3d8d3aecc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Aged</topic><topic>BCG Vaccine - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Melanoma - mortality</topic><topic>Melanoma - secondary</topic><topic>Melanoma - surgery</topic><topic>Melanoma - therapy</topic><topic>Middle Aged</topic><topic>Postoperative Care</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>Uveal Neoplasms - mortality</topic><topic>Uveal Neoplasms - surgery</topic><topic>Uveal Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McLean, Ian W.</creatorcontrib><creatorcontrib>Berd, David</creatorcontrib><creatorcontrib>Mastrangelo, Michael J.</creatorcontrib><creatorcontrib>Shields, Jerry A.</creatorcontrib><creatorcontrib>Davidorf, Frederick H.</creatorcontrib><creatorcontrib>Grever, Michael</creatorcontrib><creatorcontrib>Makley, Torrance A.</creatorcontrib><creatorcontrib>Gamel, John W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McLean, Ian W.</au><au>Berd, David</au><au>Mastrangelo, Michael J.</au><au>Shields, Jerry A.</au><au>Davidorf, Frederick H.</au><au>Grever, Michael</au><au>Makley, Torrance A.</au><au>Gamel, John W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Randomized Study of Methanol-Extraction Residue of Bacille Calmette-Guerin as Postsurgical Adjuvant Therapy of Uveal Melanoma</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>1990-11-15</date><risdate>1990</risdate><volume>110</volume><issue>5</issue><spage>522</spage><epage>526</epage><pages>522-526</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><abstract>A randomized controlled clinical trial of methanol-extracted residue of bacille Calmette-Guerin adjuvant treatment of posterior uveal melanoma was undertaken. Of 113 patients, 34 patients received adjuvant immunotherapy and 79 patients received no treatment. No difference in survival was observed between the adjuvant-treated group and the control group of patients. This study found that the size of the tumor was a highly significant risk factor for death caused by metastasis of uveal melanomas. The standard deviation of the nucleolar area of the neoplastic cells was a significant risk factor, even though patients with tumors composed of Callender's spindle-type cells were not included in the study.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>2240139</pmid><doi>10.1016/S0002-9394(14)77876-6</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9394 |
| ispartof | American journal of ophthalmology, 1990-11, Vol.110 (5), p.522-526 |
| issn | 0002-9394 1879-1891 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80116227 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adjuvants, Immunologic - therapeutic use Aged BCG Vaccine - therapeutic use Female Humans Male Melanoma - mortality Melanoma - secondary Melanoma - surgery Melanoma - therapy Middle Aged Postoperative Care Prognosis Proportional Hazards Models Risk Factors Survival Analysis Uveal Neoplasms - mortality Uveal Neoplasms - surgery Uveal Neoplasms - therapy |
| title | A Randomized Study of Methanol-Extraction Residue of Bacille Calmette-Guerin as Postsurgical Adjuvant Therapy of Uveal Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Randomized%20Study%20of%20Methanol-Extraction%20Residue%20of%20Bacille%20Calmette-Guerin%20as%20Postsurgical%20Adjuvant%20Therapy%20of%20Uveal%20Melanoma&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=McLean,%20Ian%20W.&rft.date=1990-11-15&rft.volume=110&rft.issue=5&rft.spage=522&rft.epage=526&rft.pages=522-526&rft.issn=0002-9394&rft.eissn=1879-1891&rft_id=info:doi/10.1016/S0002-9394(14)77876-6&rft_dat=%3Cproquest_cross%3E80116227%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80116227&rft_id=info:pmid/2240139&rft_els_id=S0002939414778766&rfr_iscdi=true |